Find Funding Opportunities

The purpose of this Funding Opportunity Announcement (FOA) is to encourage biomedical and behavioral research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds made available through CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and participating NIH Institute(s) and Center(s), invites applications from Institutions in African countries for research centers called H3Africa Collaborative Centers (H3ACCs). This FOA is a component of the Human Health and Heredity in Africa Initiative (H3Africa), an NIH initiative in partnership with the Wellcome Trust to develop the study, in Africa, of genomic/genetic/environmental contributors of human health and disease within Africa using cutting-edge genomic research tools, to increase capacity for biomedical research in Africa, in terms of building infrastructure (including data and research resources), and to increase the genomic proficiency of researchers and trainees in Africa. The H3Africa Initiative is focused on supporting these efforts as part of an effort to promote sustainable research in Africa that will promote health and combat disease.

The purpose of this NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and participating NIH Institute(s) and Center(s), is to invite applications from Institutions in African countries for Research Projects (U01 cooperative agreements) that address one or more goals of the Human Heredity and Health in Africa (H3Africa) initiative. H3Africa is an NIH initiative in partnership with the Wellcome Trust with the goals of developing the study of genomic/genetic/environmental contributors to human health and disease within Africa using cutting-edge genomic research tools, increasing capacity for biomedical research in Africa, in terms of building the infrastructure needed for genomic research (including data and research resources), and increasing the genomic proficiency of researchers and trainees in Africa. The H3Africa Initiative is focused on supporting these efforts as part of an effort to promote sustainable research in Africa that will promote health and combat disease.

The purpose of this Funding Opportunity Announcement (FOA) is to publicize the re-competition of Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (MDCRCs). These Centers promote collaborative basic, translational and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The centers also provide an outstanding environment for the training and career development of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Finally, center investigators are expected to participate in important community outreach and education efforts to increase awareness and convey the importance and implications of their research activities to the general public.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U01) applications from individual investigators or groups of investigators who wish to collaborate with the Epi4K Genetics and Genomics of Human Epilepsies Center without Walls (Epi4K CWOW). Investigators with existing DNA sample collections from well characterized cohorts of epilepsy patients should propose next generation sequencing and analysis studies to identify novel sequence and copy number variants. The proposed studies must be within the scope of the CWOW program and must use the extant infrastructure and resources of the Epi4K CWOW.

This Funding Opportunity Announcement (FOA) issued by the National Institute of Neurological Disorders and Stroke (NINDS) encourages applications to augment and strengthen emerging research programs focused on NINDS mission related research at institutions committed to increasing diversity in the neuroscience workforce. For the purposes of this FOA, Specialized Neuroscience Research Programs (SNRPs) are defined as those institutions with NINDS funding less than $25 million total cumulative costs over the 3 years leading up to the application. The intent of the SNRP is to promote opportunities to improve the research infrastructure at academic institutions with emerging NINDS mission related research programs to engage researchers in novel, cutting edge research. It also provides early stage investigators with the opportunity for intensive research experiences to promote scholarship in discovery, integration, and the application of knowledge in basic and translational neuroscience research.

This Funding Opportunity Announcement (FOA) invites applications for Tobacco Centers of Regulatory Science (TCORS) using the P50 mechanism. The TCORS program objective is to conduct programs of multidisciplinary research that will inform tobacco product regulation and address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The NIH and the FDA have formed an interagency partnership to foster research relevant to tobacco regulations. The awards under this FOA will be administered by NIH using designated funds from the FDA CTP for tobacco regulatory science mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. Projects resulting from this FOA are expected to serve the FDA by generating relevant findings and data needed to inform the regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

This limited competition Funding Opportunity Announcement (FOA) issued by the National Institute of Mental Health (NIMH) and the National Institute of Neurological Disease and Stroke (NINDS) solicits applications to continue the activities of the National NeuroAIDS Tissue Consortium (NNTC) Clinical Sites as previously funded under RFA-MH-08-021. The NNTC Clinical Sites collect neuromedical and neuropsychiatric data from late stage, HIV-infected subjects who have indicated a willingness to participate in organ donation. The NNTC Clinical Sites perform clinical assessments, collect brain and neurological tissues and fluids, perform neuropathological diagnosis and laboratory assessments and transfer select data generated from these activities to the NNTC central database which is maintained by the Data Coordinating Center (DCC). The mission of the NNTC is to maintain a research resource that supports studies on the pathophysiology of nervous system complications of HIV infection in the current era of anti-retroviral therapy. The Clinical Sites work cooperatively with the DCC to provide the clinical data and specimen resources to research investigators. Competitive applications for the NNTC DCC are being sought under a separate but related companion FOA (RFA-MH-13-071).

This Funding Opportunity Announcement (FOA) issued by the National Institute of Mental Health (NIMH) and the National Institute of Neurological Disease and Stroke (NINDS) seeks applications for the Data Coordinating Center (DCC) of the National NeuroAIDS Tissue Consortium (NNTC). The DCC will function as part of the NNTC, a national resource that provides clinical and research data and biological specimens to accelerate discovery research for HIV-associated central nervous system (CNS) and peripheral nervous system (PNS) diseases. It will support the NNTC Clinical Sites that are funded via the companion FOA (RFA-MH-13-070). The DCC works cooperatively with the NNTC Clinical Sites to provide (1) management and database capabilities to ensure effective clinical and brain banking operations and (2) scientific expertise in biostatistics and HIV epidemiology to enable broad analysis of the NNTC clinical database and to aid in post award statistical analysis of recruitment and retention goals for the NNTC cohort. In this consortium, the NNTC Clinical Sites will have all patient contact which will include all clinical assessments ante-mortem. The NNTC Clinical Sites will also be responsible for the collection and housing of post mortem clinical specimens. The DCC will serve as a data repository which will include the clinical assessment data and data obtained post mortem including brain pathology reports, laboratory tests conducted on the collected specimens/fluids, a comprehensive inventory of those specimens housed at each NNTC Clinical Site, and research data, such as bioinformatics datasets.

The purpose of the NIH Research Conference (R13) Grant and NIH Research Conference Cooperative Agreement (U13) Programs is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.